Anti-Aging Therapeutics Market Reach 2474.54 Million to 2031 with 17.5 percent CAGR Exclusive Report by InsightAce Analytic - Yahoo Finance
| BGT Stock | 0.04 0 2.44% |
Slightly above 62% of Bio Gene's investor base is looking to short. The analysis of overall sentiment of trading Bio Gene Technology stock suggests that many investors are alarmed at this time. Bio Gene's investing sentiment can be driven by a variety of factors including economic data, Bio Gene's earnings reports, geopolitical events, and overall market trends.
Bio |
Anti-Aging Therapeutics Market Reach 2474.54 Million to 2031 with 17.5 percent CAGR Exclusive Report by InsightAce Analytic Yahoo Finance
Read at news.google.com
 |
Bio Gene Fundamental Analysis
We analyze Bio Gene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio Gene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Gene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Book Value Per Share
Book Value Per Share Comparative Analysis
Bio Gene is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Bio Gene Technology Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Bio Gene stock to make a market-neutral strategy. Peer analysis of Bio Gene could also be used in its relative valuation, which is a method of valuing Bio Gene by comparing valuation metrics with similar companies.
Peers
Bio Gene Related Equities
| AMI | Aurelia Metals | 11.76 | ||||
| NGI | Navigator Global | 4.29 | ||||
| CIW | Clime Investment | 3.03 | ||||
| HPI | Hotel Property | 1.34 | ||||
| CIN | Carlton Investments | 0.16 | ||||
| MIR | Mirrabooka Investments | 0.59 | ||||
| FAL | Falcon Metals | 6.25 |
Additional Tools for Bio Stock Analysis
When running Bio Gene's price analysis, check to measure Bio Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Gene is operating at the current time. Most of Bio Gene's value examination focuses on studying past and present price action to predict the probability of Bio Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Gene's price. Additionally, you may evaluate how the addition of Bio Gene to your portfolios can decrease your overall portfolio volatility.